September 2019 M&A Spotlight: Hahnemann University Health Acquired

Article commentary by: Eric Murphy, Managing Director, Global Healthcare Services

Hahnemann University Health has a 496-bed academic medical center which is a tertiary care institution that specializes in bariatric surgery, cardiac services, OB/GYN, orthopedics, medical, surgical and radiation oncology, bone marrow transplantation, renal dialysis, kidney and liver transplantation and transgender surgery. It has reached an agreement to be acquired by Drexel University Endowment and Tower Health for $50 million.

  • Headquarters: Philadelphia, PA

  • Number of Beds: 496

  • Industry: Hospitals/Inpatient Services

  • Services: Academic Medical Center

  • Acquired By: Drexel University Endowment and Tower Health

  • Acquisition Date: September 20, 2019

  • Type: M&A, Private Equity

  • Deal Amount: $50M


Source: PitchBook Data, Inc., Newmark
M&A Deals represent Hospital/Inpatient Services and Clinics/Outpatient Services transactions

All information contained in this publication is derived from sources that are deemed to be reliable. However, Newmark has not verified any such information, and the same constitutes the statements and representations only of the source thereof, and not of Newmark. Any recipient of this publication should independently verify such information and all other information that may be material to any decision that recipient may make in response to this publication, and should consult with professionals of the recipient's choice with regard to all aspects of that decision, including its legal, financial, and tax aspects and implications. Any recipient of this publication may not, without the prior written approval of Newmark, distribute, disseminate, publish, transmit, copy, broadcast, upload, download, or in any other way reproduce this publication or any of the information it contains. This document is intended for informational purposes only and none of the content is intended to advise or otherwise recommend a specific strategy. It is not to be relied upon in any way to predict market movement, investment in securities, transactions, investment strategies or any other matter.

Download Our

Sign Up for Our Newsletter